Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment

Table 1 Baseline characteristics of patients in estimation and validation set

Characteristics		Estimation set (n = 146)	Validation set (n = 126)	P value
Male, n (%)		96 (65.8)	74 (58.7)	0.233^f
Age [years]^a		60.7 ± 15.0	57.8 ± 17.8	0.146^g
Body weight [kg]^a		58.3 ± 12.9	56.6 ± 14.1	0.615^g
BMI [kg/m²]^a		21.9 ± 3.9	21.5 ± 4.8	0.459^g
sCr [mg/dL]^a		0.69 ± 0.23	0.63 ± 0.24	0.025^g
eCCr [mL/min]^a		95.9 ± 43.8	109.6 ± 60.3	0.034^g
Initial VCM dose				0.049^f
> 2 g/day	n^b range [g/day]	11 (10/1/0) 2.5–4	19 (17/2/0) 2.25–3.75
= 2 g/day	n^b range [g/day]	108 (0/107/1) NA^e	77 (0/77/0) NA^e
< 2 g/day	n^b range [g/day]	27 (1/19/7) 1–1.6	30 (2/23/5) 0.5–1.5
Days until First TDM [days]^c		4 (2–7)	3 (2–6)	0.334^h
First C_trough [μg/mL]^a
All patients		13.0 ± 6.0	12.1 ± 5.4	0.185^g
> 2 g/day		13.2 ± 3.5	13.6 ± 4.1	0.821^g
= 2 g/day		13.3 ± 6.1	11.6 ± 5.5	0.056^g
< 2 g/day		11.8 ± 6.6	12.3 ± 5.7	0.743^g
BE conducted, n (%)		59 (40.4)	62 (49.2)	0.146^f
Clinical department, n				0.890^f
Hematology		27	19
Gastroenterology		13	10
Cardiology		12	12
Orthopedics		11	9
Neurosurgery		12	15
Cardiac surgery		9	5
Other		62	56
Suspected infection sites, n				0.246^f
CR-BSI^d		25	27
Febrile neutropenia		25	16
Surgical site infection		24	20
Pneumonia		12	10
Peritonitis		10	1
Cholangitis		9	6
Urinary tract infection		6	4
Cellulitis		5	5
Others		30	37

^aData are shown as mean ± standard deviation (SD)
^bNumbers in parentheses indicate the number of patients with dosing intervals of 8 h, 12 h, and others from the left, respectively
^cData are shown as median (range)
^dCatheter-related blood stream infection
^eNot applicable because all patients in =2 g/day group uniformly received 2 g/day of VCM
^fχ²-test
^gUnpaired student’s t-test
^hMann–Whitney U-test

ISSN: 2055-0294